NCT03971370View on ClinicalTrials.gov

Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine .

PHASE3CompletedINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

September 10, 2017

Primary Completion Date

September 29, 2018

Study Completion Date

February 22, 2019

Conditions
Adverse Effect and Immunogenicity of Vaccine
Interventions
BIOLOGICAL

Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)

Essen post-exposure immunization schedule at day 0,3,7,14,28.

BIOLOGICAL

Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)

Zagreb post-exposure immunization schedule at day 0,7,21.

BIOLOGICAL

Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)

Essen post-exposure immunization schedule at day 0,3,7,14,28.

Trial Locations (1)

210009

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

All Listed Sponsors
lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT03971370 - Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine . | Biotech Hunter | Biotech Hunter